Viscient is changing the way drugs are developed, using 3D human tissue models to replace the use of outdated animal models. 

Viscient's liver model was declared to contain all the characteristics of fatty liver disease by a world leading academic liver biologist Dr. David Brenner.  The model shows known disease patterns by microscopy and gene expression, as published in The American Journal of Pathology.

Using its revolutionary model, Viscient has developed one drug from start to the preclinical level and is preparing it for Phase 1 studies.  A second drug is being in-licensed for Phase 2 studies in 2024.